Scitech appointed authorised distributor for GreatEyes and BaySpec
Instrumentation supplier Scitech has been appointed the authorised distributor in Australia and New Zealand for both German-based imaging company GreatEyes and US-based spectral sensing company BaySpec.
GreatEyes develops, manufactures and markets a huge portfolio of high-performance scientific imaging and spectroscopy cameras. A combination of highly sensitive sensors with ultralow-noise electronics allows for optimal detection of weak signals which can be used in the NIR, VIS, UV, EUV and X-ray range.
The company’s products are suitable for imaging and spectroscopy applications including soft X-ray spectroscopy, plasma emission spectroscopy, fluorescence in vivo imaging, low-energy electron diffraction (LEED) imaging, thickness determination of ultrathin foils in the EUV spectrum, XUV spectroscopy and soft X-ray single shot NEXAFS spectroscopy. GreatEyes also manufactures electroluminescence and photoluminescence inspection systems for solar cells, wafers and solar modules in the solar industry.
BaySpec, meanwhile, is a designer, manufacturer and marketer of spectral instruments, including UV-VIS-NIR-SWIR spectrometers, benchtop and portable NIR/SWIR and Raman analysers, confocal Raman microscopes, hyperspectral imagers, mass spectrometers, and OEM spectral engines and components for R&D, pharmaceuticals, chemical, semiconductor and the optical telecommunications industries.
Unlike most optical device companies today, BaySpec manufactures every major component of its systems in-house in the USA. From packaging the detectors, to creating the gratings, to the control electronics and operating software, it is all done in their Silicon Valley headquarters.
Professor Tony Haymet appointed Australia's Chief Scientist
Emeritus Professor Tony Haymet — a world-leading oceanographer, chemist and entrepreneur...
NZ announces significant reforms to science sector
The reforms are intended to maximise the value of the $1.2 billion in government funding that...
Vaxxas to advance its microarray patches for COVID vaccination
Vaxxas will receive AU$3.2m from BARDA to accelerate work advancing its high-density microarray...